← All comparisons
Head-to-head · FAERS comparison

Cyclophosphamide For vs Azathioprine: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

Cyclophosphamide ForAzathioprine
Drug class–Purine Antimetabolite
Brand namesCyclophosphamide–
FAERS reports175,99387,582
Serious96%87%
Death outcome35,6418,696
Boxed warningNoYes - MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-tra

Signals both drugs share

No strong shared signal after removing coding and lab terms.

Labeled signals distinctive to Cyclophosphamide For

Labeled signals distinctive to Azathioprine

Common questions

Which has more reported side effects, Cyclophosphamide For or Azathioprine?

Cyclophosphamide For has 175,993 FAERS reports and Azathioprine 87,582. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (96% vs 87%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Cyclophosphamide For and Azathioprine share?

They share no strong flagged signal after artifacts and lab terms are removed.

Is Cyclophosphamide For or Azathioprine safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.